CD8A and hepatocellular carcinoma: Our study also showed that high levels of stem-like CD8+ Tpex could be a signature to identify HCC patients who might benefit from T + A combination therapy and the Treg/Tef ratio might be a prognostic biomarker for HCC patients with T + A combination therapy and even for all HCC patients (Fig. 7).